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ABSTRACT
Background: The mechanisms underlying body weight evolution
after diet-induced weight loss are poorly understood.
Objective: We aimed to identify and characterize differences in the
subcutaneous adipose tissue (SAT) transcriptome of subjects with
different weight changes after energy restriction–induced weight
loss during 6 mo on 4 different diets.
Design: After an 8-wk low-calorie diet (800 kcal/d), we randomly
assigned weight-reduced obese subjects from 8 European countries
to receive 4 diets that differed in protein and glycemic index con-
tent. In addition to anthropometric and plasma markers, SAT bi-
opsies were taken at the beginning [clinical investigation day (CID)
2] and end (CID3) of the weight follow-up period. Microarray anal-
ysis was used to define SAT gene expression profiles at CID2 and
CID3 in 22 women with continued weight loss (successful group)
and in 22 women with weight regain (unsuccessful group) across
the 4 dietary arms.
Results: Differences in SAT gene expression patterns between suc-
cessful and unsuccessful groups were mainly due to weight varia-
tions rather than to differences in dietary macronutrient content. An
analysis of covariance with total energy intake as a covariate iden-
tified 1338 differentially expressed genes. Cellular growth and pro-
liferation, cell death, cellular function, and maintenance were the
main biological processes represented in SAT from subjects who
regained weight. Mitochondrial oxidative phosphorylation was the
major pattern associated with continued weight loss.
Conclusions: The ability to control body weight loss independent of
energy intake or diet composition is reflected in the SAT transcrip-
tome. Although cell proliferation may be detrimental, a greater mi-
tochondrial energy gene expression is suggested as being beneficial
for weight control. This trial was registered at clinicaltrials.gov as
NCT00390637. Am J Clin Nutr 2010;92:975–84.
INTRODUCTION
Body weight maintenance after weight reduction is a major
challenge for obesity treatment. Only’20% of individuals could
be considered as successful weight-loss maintainers when
weight-maintenance success is defined as intentionally losing
10% of initial body weight and maintaining that loss for
a minimum of 1 y (1, 2). Dietary interventions are the most
popular method for weight maintenance compared with exercise
or drug-based therapies; however, there is intense debate about
what type of macronutrient is the most effective for weight
control (3, 4).
Several studies have been published regarding the effect of diet
macronutrient composition on weight reduction. Recently, Sacks
et al (5) showed no difference between dietary fat, protein, or
carbohydrate content on weight loss with the main effect caused
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Supplemental Material can be found at:
by energy restriction (ER). Because of their satiating and ther-
mogenic properties, high-protein (HP) diets have been prescribed
for both body weight loss and maintenance (6–8). In parallel,
research has focused on the type of carbohydrates in diets. The
glycemic index (GI) refers to the postprandial blood glucose
response expressed as a percentage of the response to an
equivalent carbohydrate portion of a reference food, such as
white bread or glucose (9). Reducing the insulin response by
lowering the GI in diets may lead to an improved blood glucose
profile over the late postprandial period (10), which may be
translated into a better appetite control. Previous randomized
controlled trials showed that overweight or obese people on
a low-GI (LGI) diet lost more weight than overweight or obese
people on control diet (11). However, despite the great range of
programs aimed at weight control, a poor maintenance of weight
loss in the long-term has been achieved, and the effect of
macronutrients remains to be further investigated (12, 13).
Subcutaneous adipose tissue (SAT) gene expression profiling
was shown to be a useful tool to reflect the molecular adaptations
to different dietary interventions (14). The SAT transcriptome
responds differently to caloric restriction between obese women
who were able to lose .3% of fat mass and obese women who
were not able to lose .3% of fat mass (15). Also, it seems
possible to predict the weight response of subjects to a low-fat
hypoenergetic diet by using SAT gene expression profiling be-
fore dietary intervention (16). Most of these studies focused on
caloric restriction and the effect of diet composition on SAT
gene expression during low-calorie programs. Little is known
about SAT gene expression during the clinically relevant weight
maintenance phase of dietary programs. The current work aimed
at identifying SAT gene expression patterns that discriminate
successful weight control from weight regain over a 6-mo period
in weight-reduced obese women. The dietary intervention con-
sisted of an initial 8-wk ER phase that led to a loss of 8% of
body mass followed by a 6-mo randomized controlled follow-up
period [after caloric restriction (ACR)] in which participants
consumed, ad libitum, one of 4 diets that differed in the GI and
protein amounts (17). The identification of genes associated with
the success or failure of weight stabilization may affect our
understanding of the mechanisms of weight control and provide




The study was part of the European integrated Diet, Obesity
and Genes (DiOGenes) project (17). A total of 932 overweight
and obese adults in 8 European centers (Maastrichtm, Nether-
lands; Copenhagen, Denmark; Cambridge, United Kingdom;
Heraklion, Greece; Potsdam, Germany; Pamplona, Spain; Sofia,
Bulgaria; and Prague, Czech Republic) were enrolled to par-
ticipate in a dietary intervention study aimed at defining the effect
of macronutrient diet composition on weight regain and car-
diovascular risk factors after a weight-loss period. The dietary
intervention (Figure 1) consisted of an 8-wk ER phase with
a low-calorie diet (LCD) (Modifast; Nutrition et Sante´, Revel,
France) that provided subjects with 3.3 MJ/d with the additional
consumption of 400 g raw vegetables (total energy intake of
3.3–4.2 MJ/d). A total of 773 subjects who achieved the targeted
weight loss (8% of initial body weight) during ER were se-
lected and randomly assigned to a 6-mo follow-up period re-
ferred to as the ACR phase, according to the protocol described
by Larsen et al (17). During the ACR phase, all subjects con-
sumed, ad libitum, one of 4 low-fat (25–30% of energy intake)
diets that differed in the GI and protein content. More specifi-
cally, during the 6-mo follow-up period, participants were ran-
domly assigned into one of the following dietary groups: LGI
(LGI)/low-protein (LP), high-GI (HGI)/LP, LGI/HP, and HGI/
HP diets. Target intakes in the LP diets were 10–15% of energy
intake from proteins and 57–62% of energy intake from car-
bohydrates, and in HP diets, target intakes were 23–28% of
energy intake from proteins and 45–50% of energy intake from
carbohydrates. Compared with HGI diets, LGI diets were tar-
geted with a reduction of 15 GI percentage points (18). During
the ACR phase, subjects met with a dietitian every 2 wk up to
week 6 and once a month thereafter. Weight, adverse events,
dietary compliance (by using a compliance questionnaire spe-
cifically developed for the study), and other clinical data were
collected at each visit.
Ethics
The study was approved by the local ethics committees in the
respective countries. The protocol was in accordance with the
Declaration of Helsinki (19); all study participants signed an
informed consent document after they received verbal and written
instructions and according to local legislation. Detailed in-
formation about the DiOGenes project is described by Larsen
et al (17) and Moore et al (18).
Subject selection and classification
Among the 548 subjects who completed the entire dietary
program, a subset of 227 white women was selected. Inclusion
criteria were as follows: subjects were between 20 and 50 y old,
had plasma markers that indicated that they were nondiabetic and
nondyslipidemic (total cholesterol 7 mmol/L, triglycerides
3.6 mmol/L, and fasting glucose 7 mmol/L), had a high-
quality fat biopsy and blood samples, and a full availability of
clinical information (Figure 2). Subjects were classified ac-
cording to body weight variations during the ACR phase.
Changes in weight during the ACR period were evaluated by
taking into account weight loss during ER, which was defined as
FIGURE 1. Time line for dietary intervention. At each clinical in-
vestigation day (CID), plasma samples and adipose tissue biopsies were
taken. ACR, 6 mo after caloric restriction; CID1, before energy restriction;
CID2, after 8-wk caloric restriction; CID3, 6-mo follow-up period after the
end of caloric restriction.
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S ¼ Dbody weightðCID22CID3Þ=Dbody weightðCID12CID1Þ ð1Þ
where CID corresponds to the clinical investigation day, CID1
was before the ER, CID2 was after the ER, and CID3 was after
the ACR phase (Figure 2). After exclusion of the ,10th and
.90th deciles, 22 subjects with the lowest S values were clas-
sified as successful subjects (S = 20.292 6 0.019; n = 5–6 at
each of the 4 diet branches), whereas 22 subjects with the highest
S values were classified as unsuccessful subjects (S = 0.442 6
0.017; n = 5–6 at each of the 4 diet branches) (see supplemental
Figure 1 under “Supplemental data” in the online issue).
SAT biopsy and total RNA preparation
Abdominal SAT biopsies were obtained by needle aspiration
under local anesthesia after an overnight fast at each of the CIDs
(Figure 1). All procedures were carefully harmonized among the
different centers involved. The fat samples were stored at280C
until analysis. Total RNA was extracted with the RNeasy total
RNA Mini kit (Qiagen, Courtaboeuf, France). Total RNA con-
centrations and RNA qualities were estimated by capillary
electrophoresis with the Experion analyzer (BioRad, Marnes-la-
Coquette, France).
Microarray analysis
A total of 250 ng total RNA from each sample was amplified
and transcribed into fluorescent cRNAwith Agilent’s Low RNA
Input Linear Amplification kit (Agilent Technologies, Massy,
France). A total of 88 arrays were performed by using a common
reference design: Cy5 dye was incorporated into all SAT RNA
samples, whereas a reference RNA pool made of the mix of
commercial human liver, adipose tissue, and skeletal muscle
RNA was labeled with Cy3 dye (Applied Biosystems/Ambion,
Foster City, CA). Samples were hybridized to Agilent 44K whole
human genome microarrays (Agilent Technologies), which con-
tain over 41,000 unique 60-mer oligonucleotide human se-
quences and transcripts. Sample preparations and microarray
washing were performed according to the manufacturer’s rec-
ommendations (Agilent Technologies). Arrays were scanned with
an InnoScan700 scanner (Innopsys, Carbonne, France). Images
were quantified with MAPIX V3.02 software (Innopsys). Data
analysis consisted of loess intraslide normalization followed by
quantile interslide intensity normalization with the Limma pack-
age for R-bioconductor (http://www.bioconductor.org). Intensity
ratios between Cy5 and Cy3 were filtered by using an average
intensity of 2 times above the background signal. After normali-
zation and background correction, 8423 unique genes were pres-
ent across 100% of the microarrays. The generated data set was
been submitted to the National Center for Biotechnology In-
formation (NCBI) Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/projects/geo) database (GSE19494).
Reverse transcriptase–quantitative polymerase chain
reaction
One microgram of adipose tissue total RNAwas used for first
strand cDNA synthesis by using random hexamers and poly(dT)
according to the SuperScript II reverse transcriptase kit (Invi-
trogen, Cergy Pontoise, France). All measurements were per-
formed in duplicate as previously described (20). A confirmation
set was composed of 77 subjects that included subjects selected
for the microarray study. mRNA expression levels were nor-
malized with 18S ribosomal RNA expression.
Statistical analyses
Changes in biochemical and anthropometric variables be-
tween groups (successful compared with unsuccessful groups;
and between diet branches) during the dietary intervention were
tested by using a general linear model for repeated measures with
variables adjusted for basal levels (measurements at CID1). The
effect of the diet macronutrient composition within groups was
tested by using one-factor analysis of covariance (ANCOVA) and
Bonferroni post hoc test. All statistical analyses were performed
with SPSS 17.0 software (SPSS Inc, Chicago, IL). The threshold
for statistical significance was P , 0.05.
The change in gene expression patterns during the ACR phase
was evaluated in terms of the fold change after and before the
ACR phase (CID3:CID2 ratio) in each group. Log-transformed
data were first analyzed by multivariate statistical methods by
FIGURE 2. Schematic representation of experimental design and subject
selection. A total of 548 obese adults completed the Diet, Obesity, and Genes
(DiOGenes) program. Among them, 230 women were selected by the DiO-
Genes Research, Technology, and Development line 2 (RTD2) according to
selection criteria (see section entitled “Subject selection and classification”).
Subjects were classified according to the S factor, which measures body
weight variations during the 6 mo after caloric restriction (ACR) phase in
relation to weight loss during the energy restriction (ER) phase. Subjects
with the lowest S value represented those subjects who stabilized or who
continued to lose weight (ie, the successful group). Subjects with the highest
S value represented subjects who regained weight (ie, the unsuccessful
group) during the ACR phase. A total of 39 successful and 38 unsuccessful
subjects were selected. DNA microarrays on whole subcutaneous adipose
tissue (AT) biopsies were performed in 22 successful and 22 unsuccessful
subjects (5–6 subjects at each diet branch). Validation of differential genes
identified during transcriptomic analyses were performed in the entire
successful and unsuccessful population. RT-qPCR, reverse transcriptase–
quantitative polymerase chain reaction.
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using principal components analysis (21, 22). A partial least-
square (PLS) projection to latent structures model was used to
find the relation between gene expression profiles and either diets
and response groups (PLS discriminant analysis model) or S
variable (PLS1 model). Multivariate modeling was done with
SIMCA-P+ 12 software (Urimetrics AB, Umea, Sweden). Dif-
ferences in gene expression patterns were tested with one-factor
ANCOVA by using total energy intake as a covariate when
testing for differences between successful and unsuccessful
groups; and by 2-factor ANCOVAwith diet protein amounts and
the GI as factors and with the S factor as a covariate when testing
for differences in gene expression associated to different diets.
Data were controlled for multiple testing by using Benjamini-
Hochberg P value correction. The threshold for significance was
q , 0.15.
Functional analysis was donewith Ingenuity Pathway Analysis
7.5 software (http://www.ingenuity.com; Ingenuity Systems,
Redwood City, CA) and gene set enrichment analysis (GSEA)
v 2.0 software (Broad Institute, Cambridge, MA) (23). Ingenuity
Pathway Analysis 7.5 software (Ingenuity Systems) uses
Fischer’s exact test to calculate a P value that determines the
probability that each biological function and/or disease assigned
to that data set is due to chance alone. P values were controlled
for multiple testing by Benjamini-Hochberg correction. The
GSEA v 2.0 software evaluates a query microarray data set by
using a collection of gene sets annotated in the molecular sig-
nature database and in-house gene sets (24).
RESULTS
Anthropometric and clinical data
Subjects were classified into successful or unsuccessful groups
according to weight changes during the ACR period. Biological
and anthropometrical data for both successful and unsuccessful
groups are shown in Table 1. Importantly, there were no sig-
nificant differences in any of the anthropometrical and clinical
variables before the ER between the a posteriori determined
successful and unsuccessful groups. ER led to a decrease in
body weight, fat mass, waist circumferences, systolic blood
pressure, plasma cholesterol, LDL, C-reactive protein, and in-
sulin concentrations, and homeostatic model assessment insulin
resistance. There were no significant differences in anthropo-
metrical and clinical data after ER between successful and
unsuccessful groups. After the ACR period, differences in an-
thropometrical and clinical measurements between successful
and unsuccessful groups were mainly related to weight varia-
tions between CID2 and CID3. Successful subjects had lower
body weight [D body weight(CID22CID3) = 22.6 6 1.2 kg], body
mass index, fat mass, and waist circumference, whereas these
variables were higher in unsuccessful subjects (D body
weight(CID22CID3) = +3.9 6 1.3 kg). At CID3 (ie, the end of the
ACR phase), unsuccessful subjects had higher C-reactive protein
and fasting plasma glucose concentrations compared with at
CID2 (Table 1). Plasma concentrations of total cholesterol,
HDL, and LDL were increased after the ACR phase in both
groups. Triglycerides, fructosamine, and adiponectin plasma
TABLE 1
Clinical data of subjects from successful and unsuccessful groups1
Variable
Successful (n = 39) Unsuccessful (n = 38)
CID1 CID2 CID3 CID1 CID2 CID3 P(GLM)
2
Age (y) 39.5 6 0.9 41.5 6 0.7
Weight (kg) 96.1 6 2.33,4 85.3 6 2.15 82.3 6 2.0 91.4 6 2.13,4 82.2 6 1.95 86.1 6 2.0 0.005
BMI (kg/m2) 34.3 6 6.93,4 30.5 6 0.65 29.4 6 0.9 32.3 6 6.93,4 29.6 6 0.65 31.0 6 0.7 0.001
Fat mass (%) 43.7 6 1.03,4 39.5 6 1.05 37.8 6 0.9 43.7 6 0.83,4 38.5 6 1.25 41.3 6 0.9 0.001
Waist circumference (cm) 103.1 6 1.03,4 94.6 6 1.55 91.4 6 1.5 101.7 6 1.93,4 94.0 6 1.95 97.4 6 1.9 0.001
SBP (mm Hg) 120.2 6 2.03 115.2 6 1.9 117.0 6 2.0 121.1 6 2.23 113.0 6 2.25 120.0 6 2.1 0.921
DBP (mm Hg) 74.5 6 1.53 71.1 6 1.3 70.7 6 1.4 73.0 6 1.6 70.5 6 1.8 72.6 6 1.8 0.314
Cholesterol (mmol/L) 4.7 6 0.13 4.1 6 0.15 4.6 6 0.1 4.8 6 0.13 4.3 6 0.25 4.8 6 0.1 0.761
HDL (mmol/L) 1.26 6 0.053,4 1.16 6 0.045 1.44 6 0.05 1.32 6 0.063,4 1.21 6 0.055 1.45 6 0.06 0.517
LDL (mmol/L) 2.89 6 0.113,4 2.50 6 1.105 2.69 6 0.10 2.96 6 0.113 2.53 6 0.125 2.82 6 0.10 0.705
Triglycerides (mmol/L) 1.28 6 0.053 1.05 6 0.05 1.05 6 0.06 1.29 6 0.10 1.21 6 0.15 1.26 6 0.73 0.719
Fructosamine (lmol/L) 206.6 6 3.8 210.9 6 3.2 213.1 6 3.0 207.3 6 3.8 206.2 6 4.5 216.0 6 3.4 0.185
Adiponectin (lg/mL) 9.4 6 0.7 9.8 6 0.5 10.6 6 0.5 9.6 6 0.7 10.4 6 0.8 12.2 6 0.8 0.278
C-reactive protein (mg/mL) 5.6 6 0.93,4 4.7 6 0.7 3.5 6 0.6 4.8 6 0.83 3.0 6 0.75 4.1 6 0.9 0.001
Fasting glucose (mmol/L) 5.0 6 0.1 4.8 6 0.1 4.7 6 0.1 5.1 6 0.13 4.8 6 0.15 5.0 6 0.1 0.018
Fasting insulin (lIU/mL) 9.9 6 0.83,4 7.5 6 0.75 6.6 6 0.6 11.4 6 1.33,4 8.0 6 0.85 8.6 6 0.8 0.115
HOMA-IR 1.32 6 0.113,4 0.96 6 0.09 0.90 6 0.07 1.52 6 0.173,4 1.12 6 0.10 1.17 6 0.11 0.170
1 All values are means 6 SEs. CID1, clinical investigation day before energy restriction; CID2, clinical investigation day after 8-wk caloric restriction;
CID3, clinical investigation day 6 mo after the end of caloric restriction; GLM, general linear model; SBP, systolic blood pressure; DBP, diastolic blood
pressure; HOMA-IR, homeostasis model assessment of insulin resistance. The table includes anthropometric and plasma variables at CID1, CID2, and CID3 in
39 women with sustained weight loss (ie, the successful group) and 38 women regaining weight (ie, the unsuccessful group) among the 4 dietary arms. There
was no significant difference between successful and unsuccessful groups at CID1 and CID2.
2 GLM for repeated measures was used to test differences in clinical data during the ACR (after caloric restriction) phase between successful and
unsuccessful groups. Levels at CID1 were taken as covariates.
3 P , 0.05 between CID1 and CID2 as determined by one-factor ANOVA and Bonferroni post hoc test between CIDs for each group separately.
4 P , 0.05 between CID1 and CID3 as determined by one-factor ANOVA and Bonferroni post hoc test between CIDs for each group separately.
5 P , 0.05 between CID2 and CID3 as determined by one-factor ANOVA and Bonferroni post hoc test between CIDs for each group separately.
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concentrations remained constant in successful and unsuccessful
subjects after the ACR phase. Diet compositions had no effect
on anthropometrical and biochemical variables for either suc-
cessful or unsuccessful subjects (see supplemental Tables 1 and
2 under “Supplemental data” in the online issue).
Differences in eating behaviors between the 2 groups were
evaluated by 3-d dietary records through which the total energy
intake at the end of the ACR period was estimated (18). There
was no significant difference in energy intake among diet groups,
but unsuccessful subjects ingested more energy than successful
subjects (6.23 6 2.60 and 6.78 6 2.04 MJ/d, respectively; P ,
0.02) (data not shown).
Change in adipose tissue gene expression patterns in
successful and unsuccessful subjects
A subset of 22 successful and 22 unsuccessful subjects (5 or 6
subjects at each diet branch) with high RNA quality and clinically
representative of both groups was selected for microarray
analysis. The change in gene expression patterns after ER was
tested in terms of fold change after and before the ACR period for
each group (CID3:CID2 ratio).
The data set was monitored by both multivariate principal
component analysis and univariate 3-factor analysis of variance
with or without control for differences in energy intake. All
analyses showed that the main source of variation in the gene
expression data set was the difference between successful and
unsuccessful groups (see supplemental Figure 2 under “Sup-
plemental data” in the online issue).
To determine whether global gene expression changes during
ACR could differentiate between subject groups, PLS discrim-
inant analysis was performed. There were no gene expression
patterns associated with macronutrient diet composition; how-
ever, there was a slight but not significant separation between
successful and unsuccessful groups [R2 = 0.115 and Q2 = 0.067,
where R2 explained the cumulative variation of the 2 first
components and Q2 indicated the variation explained by the
model according to cross-validation (21)] (Figure 3A). With the
use of a model for explaining differences in S values and, hence,
differences between successful and unsuccessful subjects, in-
dependent of diet compositions, there was a significant separa-
tion between successful and unsuccessful groups (R2 = 0.813;
Q2 = 0.88) (Figure 3C). Similarly, differences in clinical data
were more associated with the differences in S values than with
diet compositions (R2 = 0.113 and Q2 = 0.044 and R2 = 0.851
FIGURE 3. Exploratory analyses of gene expression and clinical data. Partial least-squares (PLS) regression was used to determine differences in gene
expression patterns (A and C) or to correlate clinical data (B and D) with different groups. A: Score plot of PLS discriminant analysis (PLS-DA) used for
explaining differences between groups and diets (R2 = 0.115, Q2 = 0.067). B: Loadings bi-plot of PLS-DA correlating clinical data with groups and diets (R2 =
0.113, Q2 = 0.044). C: Score plot of PLS1 model for explaining the S factor by gene expression patterns (R2 = 0.813, Q2 = 0.88) (successful subjects are shown
inside the dark ellipse; unsuccessful subjects are shown inside the gray ellipse). D: Loading bi-plot of PLS1 model showing the correlation of clinical variables
with the S factor (R2 = 0.851, Q2 = 0.766). t[1] and t[2] correspond to the visualized principal components 1 and 2, respectively. Axes in B and D correspond to
the correlation coefficient between the first component of the clinical data (pc(corr)[1]) and the first component of the gene expression data (t(corr)[1]).
Ellipses in A and C correspond to the confidence ellipse on the basis of Hotelling T2 at a 0.05 significance level. Ellipses in B and D correspond to the
correlation ratios of 0.5, 0.75, and 1 in the dotted, slashed, and solid ellipses, respectively. R2 explains the variation of the first component, and Q2 indicates the
variation explained by the model according to cross validation. Q2 . 0.5 indicates a good model. Triangle, low–glycemic index (LGI)/low-protein (LP) diet;
box, high-glycemic index (HGI)/LP diet; circle, LGI/high-protein (HP) diet; diamond, HGI/HP diet; black symbols, successful group; gray symbols, un-
successful group; CRP, C-reactive protein; FM, fat mass; DBP, diastolic blood pressure; SBP, systolic blood pressure; TotEnergy, total energy.
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and Q2 = 0.766, respectively) (Figure 3, B and D). Variables
accounting for group separation were selected by using the
variable importance in the projection (VIP) score. Variables with
a VIP .1 were those highly associated to differences in phe-
notypes. Eighty-eight transcripts had a VIP .1 and were con-
sidered as differential between successful and unsuccessful
groups (see supplemental Table 3 under “Supplemental data” in
the online issue).
To avoid confounding effects for differences in total energy
intakes between groups during the ACR period, a one-factor
ANCOVAwith total energy intake as a covariant was performed.
There were 1338 significant genes (P , 0.03; q , 0.15) (see
supplemental Table 3 under “Supplemental data” in the online
issue). Importantly, 60 of the 88 transcripts with a VIP.1 in the
multivariate model were also significant by ANCOVA with
a false discovery rate (FDR) ,5% (Table 2). Among these, 34
genes were up-regulated in unsuccessful subjects and down-
regulated in successful subjects and 26 genes were up-regulated
in successful subjects and down-regulated in unsuccessful sub-
jects (see supplemental Figure 3 under “Supplemental data” in
the online issue).
As suggested by exploratory analyses, differences in SAT gene
expression patterns between successful and unsuccessful groups
were mainly due to weight variations rather than to differences in
diet macronutrient composition. To confirm this, a 2-factor
ANCOVA with the S factor as a covariant was performed. No
significant differences in gene expression were shown (q . 0.90).
Microarray data were confirmed by reverse transcriptase–
quantitative polymerase chain reaction (RT-qPCR) analysis for
31 genes. RT-qPCR was performed in the whole successful and
unsuccessful populations (n = 39 and 38, respectively) (see
supplemental Table 4 under “Supplemental data” in the online
issue). There was a good concordance between microarray and
RT-qPCR data. Changes in expression of all but 4 genes were
confirmed.
Biological and functional analysis
The main biological processes involving the 1338 differential
genes were evaluated by different approaches. For better data
interpretation, we calculated the unsuccessful:successful ratio,
and all functional analyses were performed by using this ratio.
Biological functions analyzed by Ingenuity Pathway Analysis 7.5
software (Ingenuity Systems) showed that cellular growth and
proliferation, gene expression, RNA posttranscriptional modifi-
cation, and cellular function and maintenance functions were
enriched in differential genes compared with the biological
functions represented on the entire microarray (Figure 4A). The
associated networks corresponded to cancer, cell death, gene
expression, RNA posttranscriptional modification, and cellular
functional modification gene functions (see supplemental Figure
4 under “Supplemental data” in the online issue). Genes in
cellular growth and proliferation, gene expression, and cellular
function and maintenance biological functions were more ex-
pressed in unsuccessful subjects, whereas genes associated with
the RNA posttranscriptional modification biological function
were more expressed in successful subjects (Figure 4B).
Pathways associatedwith differentially expressed geneswere also
assessed with GSEA v 2.0 software. The GSEA v 2.0 software
showed 247 gene sets collected on the molecular signature database
(MSigDB) of the GSEA software associated with the list of 1338
genes ranked in decreasing expression ratio between unsuccessful
and successful subjects. Among these, 14 gene sets were enriched in
the unsuccessful group (FDR 5%), and one gene set that was
related to mitochondrial function (25) (MOOTHA_VOXPHOS gene
set) was enriched in the successful group (FDR = 2.0%) (see
supplemental Table 5 under “Supplemental data” in the online is-
sue). Among those gene sets that were enriched in unsuccessful
subjects, AT_LONGITUDINAL_WEIGHT_LOSS_WS_DOWN and
AT_LONGITUDINAL_WEIGHT_LOSS_DI_DOWN gene sets were
in house–generated gene sets that corresponded to abdominal
SAT genes down-regulated in subjects maintaining weight after
LCD-induced weight loss (26). Four of the gene sets were
enriched in successful subjects as follows: INOS_ALL_DN, TGF_
BETA_SIGNALING_PATHWAY, NING_COPD_UP, JISON_
SCICKLECELL_DIFF, and encompass inflammation-related
genes. Two other gene sets, PROLIFERATION_GENES and
CELL_PROLIFERATION, were related to cell proliferation.
DISCUSSION
An important challenge in obesity management is the long-term
maintenance of weight reduction. New strategies for successful
body weight maintenance after weight loss are required. To prevent
weight regain, the knowledge of themechanisms involved inweight
control should first be elucidated. In the current study, we examined
the change in SAT gene expression patterns 6 mo after LCD-
induced weight loss. Our results showed differences between
subjects who continue to lose weight and subjects who regained
weight independent of the diet-macronutrient composition and total
energy intake.
The DiOGenes program is a European, multicenter, dietary
intervention trial in overweight and obese subjects. Low-fat diets
with different protein amounts and GI were assigned to weight-
reduced obese subjects (17, 18). Our main purpose was to in-
vestigate SAT mRNA to identify gene biomarkers of weight
control during the ACR follow-up period. Subject selection was
made to better identify genes that accounted for successful weight
control without confounding effects that were due to extreme
diet-induced weight variations and, in parallel, to search for gene-
diet interactions without confounding effects that were due to
weight variations. SAT transcriptome changes after the 6-mo
ACR period were mainly due to weight variations independent of
diet macronutrient composition; however, it is possible that the
subtle effects of varying macronutrient content were masked by
weight variations. When subjects from the same group (ie, either
the successful or unsuccessful group) were clinically matched
across the 4 diet branches, a similar distribution in weight
evolution was observed. More specifically, subjects were under
conditions of weight regain (22.6 6 1.2 kg, which represented
27% of the weight lost while consuming the LCD) or loss (+3.96
1.3 kg, which represented 42% of the weight lost while consuming
the LCD) for unsuccessful and successful subjects, respectively.
SAT might respond to weight variations first and foremost, as seen
in previous works in which ER was the main factor that accounted
for changes in SAT gene expression (20, 27).
One of the features of the DiOGenes programwas that post-ER
diets were given ad libitum (18). As expected, energy intake in
unsuccessful subjects was higher than in successful subjects
during the 6-mo ACR period. Because SAT responds to energy
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Differentially expressed genes between subjects who succeeded and subjects who failed weight control, independent of energy intake1
Gene
symbol Accession code Description Biological process
Unsuccessful:successful
ratio
NOMO1 NM_014287 NODAL modulator 1 Carbohydrate binding 1.99
TPCN1 AB032995 mRNA for KIAA1169 protein Cation transport 0.73
FTL NM_000146 Ferritin, light polypeptide Cation transport and other homeostasis
activities
1.36
CFL1 NM_005507 Cofilin 1 Cell structure 1.87
CFLP1 BC031631 Cofilin pseudogene 1 Cell structure 1.73
SPTAN1 NM_003127 Spectrin, alpha, nonerythrocytic 1 Cell structure 1.67
ARPC1A NM_006409 Actin related protein 2/3 complex,
subunit 1A
Cell structure 1.35
MSH6 NM_000179 MutS homolog 6 DNA repair and meiosis 0.76
PHB2 NM_007273 Prohibitin 2 DNA replication, cell-cycle control, and cell
proliferation and differentiation
1.32
MCM3 NM_002388 MCM3 minichromosome maintenance
deficient 3
DNA replication 0.70
EHD4 NM_139265 EH-domain containing 4 Endocytosis and neurotransmitter release 1.47
ARF3 NM_001659 ADP-ribosylation factor 3 General vesicle transport 1.44
PKM2 NM_182470 Pyruvate kinase, muscle, transcript variant 2 Glycolysis 1.83
PGAM1 NM_002629 Phosphoglycerate mutase 1 Glycolysis 1.51
GIT2 NM_139201 G protein–coupled receptor kinase interactor
2, transcript variant 4
G protein–mediated signaling, cell adhesion,
and cell structure and motility
0.63
DNAJC13 NM_015268 DnaJ (Hsp40) homolog, subfamily C,
member 13
Heat shock protein binding 1.63
AP2M1 NM_004068 Adaptor-related protein complex 2, mu 1
subunit, transcript variant 1
Intracellular protein transport 1.74
LASS2 NM_181746 LAG1 homolog, ceramide synthase 2,
transcript variant 1
Lipid metabolism, developmental processes,
and other metabolism
1.41
HLA-C ENST00000383620 Major histocompatibility complex, class I, H MHCI-mediated immunity 1.25
SNTB2 NM_006750 Syntrophin, beta 2 Neuromuscular synaptic transmission 0.64
NUP62 NM_153719 Nucleoporin 62 kDa, transcript variant 1 Nuclear transport 0.73
PWP1 NM_007062 PWP1 homolog Nucleoside, nucleotide, and nucleic acid
metabolism
0.75
TDRD7 NM_014290 Tudor domain containing 7 Nucleoside, nucleotide, and nucleic acid
metabolism
0.71
NDUFA9 NM_005002 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 9, 39 kDa
Oxidative phosphorylation 0.80
AGPAT1 NM_006411 1-Acylglycerol-3-phosphate O-
acyltransferase 1
Phospholipid metabolism 1.37
RNF5 NM_006913 Ring finger protein 5 Protein binding 1.34
BTBD7 NM_018167 BTB (POZ) domain containing 7, transcript
variant 2
Protein binding 0.73
RPL6 NM_001024662 Ribosomal protein L6, transcript variant 1 Protein biosynthesis 1.41
RPN1 NM_002950 Ribophorin I Protein biosynthesis, protein glycosylation,
and other metabolism
1.42
EIF4A1 NM_001416 Eukaryotic translation initiation factor 4A,
isoform 1
Protein biosynthesis and translational
regulation
1.47
RPLP0 NM_053275 Ribosomal protein, large, P0, transcript
variant 2
Protein biosynthesis and translational
regulation
1.36
RPLP0P2 NR_002775 Ribosomal protein, large, P0 pseudogene 2,
on chromosome 11
Protein biosynthesis and translational
regulation
1.33
LOC646875 XM_929836 60S ribosomal protein L12 Protein biosynthesis and translational
regulation
1.30
Unknown THC2521188 RL9_Human P32969 60S ribosomal
protein L9
Protein biosynthesis and translational
regulation
0.52
KCTD20 NM_173562 Potassium channel tetramerisation domain
containing 20
Protein folding 1.72
TPST2 NM_001008566 Tyrosylprotein sulfotransferase 2, transcript
variant 1
Protein modification 1.76
PKIG NM_181805 Protein kinase (cAMP-dependent, catalytic)
inhibitor gamma, transcript variant 1
Protein modification and signal transduction 1.49
(Continued)
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intake on the basis of an organism’s energy requirements (20, 28),
we performed an ANCOVA to avoid confounding effects related
to differences in energy intake. The differentially expressed genes
shown in the current study represent the expression patterns that
differentiated subjects who continued to lose weight from sub-
jects who regained weight, independent of total energy intake.
Sixty significant genes were common to both ANCOVA (FDR,
5%) and multivariate analyses (VIP .1). Although these genes
do not belong to a common and unique biological function or
pathway, and some of them are currently unknown genes, they
are of interest because they represent the genes that accounted
for most of the group separation, independent of energy intake
and differences in diet macronutrient composition.
Among these genes, E2F transcription factor 4 (E2F4) was up-
regulated in unsuccessful subjects. E2F4 is a member of the
E2F family of transcription factors. The E2F family plays
a crucial role in the control of cell cycle. In SAT, the E2F family
plays an important role during adipogenesis by regulating the
expression of peroxisome proliferator–activated receptor c.
Specifically, E2F4 represses the expression of peroxisome
proliferator–activated receptor c during terminal adipocyte dif-
ferentiation (29). The differential expression of E2F4 between
successful and unsuccessful subjects suggested a possible de-
regulation of adipocyte differentiation between subjects who
succeeded and subjects who failed weight maintenance. More-
over 7 genes (ie, RPL6, RPN1, EIF4A1, RPL0, RPLP0P2,
LOC64875, and RL9) that coded for ribosomal proteins were
also up-regulated in unsuccessful subjects. This may also sug-
gest a deregulation of adipogenesis in unsuccessful subjects.
This coincides with recent findings by Todorcevic et al (30), in
which the authors showed that genes coding for ribosomal
machinery were down-regulated in adipose tissue–derived
stroma-vascular fraction cells that differentiated into adipocytes
in Atlantic salmon.
For better interpretation of gene expression data, the 1338
differential genes were ranked according to decreasing fold
change between unsuccessful and successful groups. The func-
tional analysis of ranked gene lists showed opposite expression
patterns between genes related to inflammation and cell pro-
liferation and genes related to mitochondrial function.
Although genes associated with inflammatory pathways and
cell proliferation were up-regulated in unsuccessful subjects and
TABLE 2 (Continued )
Gene
symbol Accession code Description Biological process
Unsuccessful:successful
ratio
MAPK3 NM_002746 Mitogen-activated protein kinase 3 Protein phosphorylation and signal
transduction
1.65
KLK3 AJ310938 mRNA for putative preproPSA-RP2,
transcript 2
Proteolysis 0.35
CLTB NM_007097 Clathrin, light-chain, transcript variant 2 Receptor-mediated endocytosis 1.51
SRP9 NM_003133 Signal recognition particle 9 kDa Signal recognition particle binding 0.68
SH3BGRL NM_003022 SH3 domain binding glutamic acid-rich
protein like
Signal transduction and SH3 domain binding 1.58
E2F4 NM_001950 E2F transcription factor 4, p107/p130-
binding
Signal transduction and cell proliferation and
differentiation
1.32
CDK2AP1 NM_004642 CDK2-associated protein 1 Signal transduction and cell proliferation and
differentiation
1.44
VGLL3 NM_016206 Vestigial like 3 (Drosophila) Transcription regulation 0.63
BF869497 BF869497 BF869497 IL3-ET0115-091000–286-D05
ET0115 cDNA
Biological process unclassified 2.22
AK057071 AK057071 cDNA FLJ32509 fis, clone SMINT1000054 Biological process unclassified 1.62
LOC284361 NM_175063 Hematopoietic signal peptide-containing,
transcript variant HSS1
Biological process unclassified 1.46
MGC71993 NM_001004333 DNA segment, chromosome 11 Biological process unclassified 1.43
Unknown KIAA1545 Unknown Biological process unclassified 1.43
C16orf14 NM_138418 Chromosome 16 open reading frame 14 Biological process unclassified 1.36
C6orf48 NM_001040437 Chromosome 6 open reading frame 48,
transcript variant 1
Biological process unclassified 0.75
TNRC6B NM_015088 Trinucleotide repeat containing 6B,
transcript variant 1
Biological process unclassified 0.72
AK123757 AK123757 cDNA FLJ41763 fis, clone IMR322005293 Biological process unclassified 0.72
C6orf203 NM_016487 Chromosome 6 open reading frame 203 Biological process unclassified 0.68
Unknown THC2696916 Q2NF74_METST (Q2NF74) Predicted
dinucleotide-utilizing protein
Biological process unclassified 0.68
C10orf12 NM_015652 Chromosome 10 open reading frame 12 Biological process unclassified 0.63
AF086126 AF086126 Full length insert cDNA clone ZA79F02 Biological process unclassified 0.56
LOC642826 AK096908 cDNA FLJ39589 fis, clone SKMUS2008607 Biological process unclassified 0.53
Z69892 Z69892 Clone ICRFp507I1077 Biological process unclassified 0.39
1 The table includes genes with a variable importance in the projection score .1 in the multivariate model partial least square projection to latent
structure (PLS1) and a false discovery rate cutoff of 5% in the univariate model (ANCOVA) with energy intake as a covariate. See text for details.
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down-regulated in successful subjects, genes that encoded mi-
tochondrial function–associated proteins showed the opposite
pattern. In vitro coculture studies have shown that human pre-
adipocytes exhibit a greater capacity to proliferate in the presence
of an inflammatory microenvironment (ie, human macrophage
medium) (31). Whether the proliferative pattern in white adipose
tissue is related to adipose-cell precursors is still unknown; but
when taken together, these results suggest that the inability to
control weight is related to increased inflammation and mito-
chondrial impairment in SAT. The role of mitochondrial func-
tions during adipogenesis and in mature adipocytes has been
recently reviewed by De Pauw et al (32). Mitochondrial dys-
function could result in cellular disruptions that could be related
to complications associated with obesity via modifications of
lipid metabolism and energy partitioning. Mice with systemic
impairment of oxidative phosphorylation are more sensitive to
obesity and to diabetes mellitus than control mice when fed
a high-calorie diet under the same conditions of energy intake and
physical activity (33). In humans, it has been shown that oxidative
phosphorylation genes are also down-regulated in white adipose
tissue of morbidly obese subjects compared with lean subjects,
whereas after surgery-induced weight loss, an up-regulation of
these genes was observed (34). An opposite pattern was seen for
inflammatory genes in the present study. Whether the down-
regulation of mitochondrial genes observed in unsuccessful
subjects is a cause or consequence of weight gain needs to be
elucidated, but these results open the door to new hypotheses
regarding metabolic adaptations and their importance for weight
control.
In conclusion, we showed that the abdominal SAT tran-
scriptome reflects the capacity to maintain body weight. To our
knowledge, this is the first report to show that SAT gene ex-
pression patterns differ between subjects who continue to lose
weight after an ER phase and individuals who regain weight.
Moreover, these changes are independent of energy intake.
Because weight variations could mask possible diet-gene inter-
actions, we are now characterizing the SAT transcriptome of
subjects with minimal weight variations during the DiOGenes
dietary intervention program.
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